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Mathematical models of cytotoxic eﬀects in
endpoint tumor cell line assays: critical assessment
of the application of a single parametric value as a
standard criterion to quantify the dose–response
eﬀects and new unexplored proposal formats†
Ricardo C. Calhelha,a Mireia A. Martínez,a M. A. Prieto *a,b and
Isabel C. F. R. Ferreira *a
The development of convenient tools for describing and quantifying the eﬀects of standard and novel
therapeutic agents is essential for the research community, to perform more precise evaluations.
Although mathematical models and quantiﬁcation criteria have been exchanged in the last decade
between diﬀerent ﬁelds of study, there are relevant methodologies that lack proper mathematical descrip-
tions and standard criteria to quantify their responses. Therefore, part of the relevant information that can
be drawn from the experimental results obtained and the quantiﬁcation of its statistical reliability are lost.
Despite its relevance, there is not a standard form for the in vitro endpoint tumor cell lines’ assays (TCLA)
that enables the evaluation of the cytotoxic dose–response eﬀects of anti-tumor drugs. The analysis of all
the speciﬁc problems associated with the diverse nature of the available TCLA used is unfeasible.
However, since most TCLA share the main objectives and similar operative requirements, we have chosen
the sulforhodamine B (SRB) colorimetric assay for cytotoxicity screening of tumor cell lines as an experi-
mental case study. In this work, the common biological and practical non-linear dose–response mathe-
matical models are tested against experimental data and, following several statistical analyses, the model
based on the Weibull distribution was conﬁrmed as the convenient approximation to test the cytotoxic
eﬀectiveness of anti-tumor compounds. Then, the advantages and disadvantages of all the diﬀerent para-
metric criteria derived from the model, which enable the quantiﬁcation of the dose–response drug-
eﬀects, are extensively discussed. Therefore, model and standard criteria for easily performing the com-
parisons between diﬀerent compounds are established. The advantages include a simple application, pro-
vision of parametric estimations that characterize the response as standard criteria, economization of
experimental eﬀort and enabling rigorous comparisons among the eﬀects of diﬀerent compounds and
experimental approaches. In all experimental data ﬁtted, the calculated parameters were always statisti-
cally signiﬁcant, the equations proved to be consistent and the correlation coeﬃcient of determination
was, in most of the cases, higher than 0.98.
1. Introduction
A wide range of in vitro TCLA endpoint assays have been
developed for the discovery of therapeutic molecules,1 investi-
gation of their mechanisms of action,2–4 and study of signal
transduction, cell division, and other biological processes
using chemical biology approaches.5 In general, these assays
use established tumor cell lines from human patients or
animals and diﬀer in the mechanism of displaying the tumor
cell response and/or target molecules, and in the end pro-
ducts measured. The methods described include tetrazolium
reduction (MTT, MTS, XTT, and WST-1), resazurin reduction,
sulforhodamine B (SRB), protease markers, and ATP
detection.6–8 Each assay has its own set of advantages and
disadvantages and it is diﬃcult to point to the most con-
venient assay that conducts the best evaluation. These
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techniques still left many open questions, only ranking the
cytotoxicity in their reaction system.
Originally, most TCLA were performed in a “single-test”
response format, and the cell counts were determined after
several steps, preventing researchers from testing a large number
of samples simultaneously. At that time, the lack of proper appli-
cation of mathematical models turned out simple formalisms,
which were more practical.9,10 Since the development of equip-
ment able to perform multiple analyses (such as microplate
readers), new protocols have been developed to reconfigure the
methods extending the applicability of the methodologies,
enabling higher numbers of samples, reducing the quantity of
reagents and increasing the precision and reproducibility.11
Although consistent response results are obtained with
TCLA, the quantification of the results has been left in the
oldest format with simple calculation formalisms to abbreviate
the testing procedure. The quantification relies on the deter-
mination of the dose that would decrease the tumor cell popu-
lation down to 50%, commonly known as the 50% lethal dose
(LD50). Although cytotoxic results are expressed fundamentally
by the LD50 values, other typical metric values are also used
such as the fraction of viable cells at the highest agent concen-
tration (Emax) or the area under the dose–response curve
(AUC).5 Their calculation can be obtained by non-mathemat-
ical means (graphical analysis, linear interpolations, etc.) or by
mathematical expressions (typically by sigmoidal curves). The
application of non-mathematical means has caused much con-
troversy because: (1) the LD50 values are less reproducible and
highly depend on the slope of the response;12 (2) it prevents
the quantification of its statistical reliability;9 (3) increases the
accumulation of procedural restrictions that over-standardize
the protocol;13 and (4) loses a part of the relevant information
that can be drawn from the experimental results.14 When
mathematical expressions are applied, comprehensive metric
information of the dose–response is provided. However, a
variety of mathematical models (from 2 to 5 parameter curves),
the range and number of doses, among other experimental
factors, has recently been determined for large-scale drug-
response, in which data responses vary unacceptably between
diﬀerent studies.5,15–18
The analysis of all the problems of TCLA with the diverse
quantification criteria used for each method is unfeasible.
However, since most of the methods share the main objectives
and operative requirements,6,19 the SRB colorimetric assay for
cytotoxicity screening of tumor cell lines has been chosen as a
case study. The SRB assay is a well-accepted model for testing
cytotoxicity and is a highly reproducible procedure, currently
performed using microplate readers, providing an appropriate
tool which ensures that samples and controls of the reaction
can be simultaneously assessed, producing abundant data
with lower experimental error.8 It is, therefore, a robust and
meaningful example that can be used as a case study for devel-
oping criteria to evaluate and compare the cytotoxicity process
of TCLA.
In mathematical terms, there are several approaches that
can be transferred from microbiology, enzymology, pharmaco-
logy, among other dose–response fields, to describe the
complex mortality process of tumor cell lines.11,20–24,26 In fact,
from the dose–response theory, the two parameter (2P)
equations (such as the Bertalanﬀy and Michaelis–Menten
equations) and the three parameter (3P) sigmoidal group of
functions (such as the logistic, Weibull, Hill, Gompertz,
Richards–Chapman, among others) would be, in general,
acceptable solutions to fit individually the dose–response pro-
files corresponding to the cytotoxic responses of tumor cells
after being treated with individual or a mixture of compounds.
In general, these models would improve, aid and guide
researchers to compute and, occasionally, to precisely predict
the results obtained in TCLA. These models would be able to
produce key parameters to summarize the responses, such as
the asymptote, LD50, maximum and average rate processes or
the lag-phase period values, among others.
In this work, the most biologically relevant and practical
non-linear dose–response mathematical models were tested
against the experimental data obtained. Their fitting results
were evaluated with diﬀerent statistical criteria to rank the
suitability of the mathematical equations for describing TCLA
responses. The most satisfactory solution was determined and
when properly applied, it would certainly improve the
eﬃciency and precision of the description, characterization,
quantification and prediction of TCLA. The advantages are a
simple application, provision of parametric estimations that
characterize the response, simplification of the protocol,
economization of experimental eﬀort and facilitation of
rigorous comparisons among the eﬀects of diﬀerent com-
pounds and experimental approaches.
2. Materials and methods
2.1. Reagents
Cell lines HeLa, NCI-H460 and MCF-7 were purchased from
Deutshe Sammlung von Mikroorganismen and Zellkulturen
Gmbit (DSMZ). Dulbecco’s modified Eagle’s medium (DMEM),
Hank’s balanced salt solution (HBSS), fetal bovine serum
(FBS), L-glutamine, trypsin-EDTA, penicillin/streptomycin solu-
tion (100 U mL−1 and 100 mg mL−1, respectively) were pur-
chased from Gibco Invitrogen Life Technologies (Carlsbad, CA,
USA). Water was treated in a Milli-Q water purification system
(TGI Pure Water Systems, Greenville, SC, USA). The anti-tumor
agents ellipticine (EL), cisplatin (CDDP) and etoposide (VP-16)
were purchased at Adooq Bioscience (Irvine, CA).
2.2. Anti-tumor agents
2.2.1. Commercial agents. Stock solutions of 10 mM were
prepared for each commercial agent. The solvent used for EL
and VP-16 was DMSO, whereas phosphate buﬀered solution
(PBS, 1 M) was used for CDDP.
2.2.2. Natural agents. In this study, two of the classical
solvents with diﬀerent degrees of polarity were used to
extract the anti-tumor agents previously identified in Achillea
millefolium L.25 Briefly:
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- Methanol extraction (ME): One gram was extracted twice
by stirring with 30 mL of methanol (25 °C at 150 rpm) for 1 h
and afterwards the solvent was evaporated at 40 °C to dryness.
- Water extraction (WE): One gram was added to 200 mL of
boiling distilled water and left to stand at room temperature
for 5 min, and then filtered under reduced pressure. The
obtained extracts were frozen and lyophilized.
2.3. Evaluation of the cytotoxic properties by the
sulforhodamine B colorimetric assay
Four human tumor cell lines were used: MCF-7 (breast adeno-
carcinoma), NCI-H460 (non-small cell lung carcinoma), HeLa
(cervical carcinoma) and HepG2 (hepatocellular carcinoma).
Cells were routinely maintained as adherent cell cultures in
RPMI-1640 medium containing 10% heat-inactivated FBS and
2 mM glutamine (MCF-7, NCI-H460 HeLa and HepG2 cells), at
37 °C, in a humidified air incubator containing 5% CO2. Each
cell line was plated at an appropriate density (1.0 × 104 cells
per well in 200 μL of final volume) in 96-well plates and
allowed to attach for 24 h. The cells were then incubated for
48 h with various extract concentrations. Following this incu-
bation period, the adherent cells were fixed by adding cold
10% trichloroacetic acid (TCA, 100 µL) and incubated for
60 min at 4 °C. Plates were then washed with deionized water
and dried; sulforhodamine B solution (0.1% in 1% acetic acid,
100 µL) was then added to each plate well and incubated for
30 min at room temperature. Unbound SRB was removed by
washing with 1% acetic acid. Plates were air dried, the bound
SRB was solubilized with 10 mM Tris (200 µL) and the absor-
bance was measured at 540 nm.
Natural agents were dissolved in water, meanwhile commer-
cial agents were dissolved in DMSO. Initial experiments were
carried out to determine the dose range that will describe the
profile from none to maximum cytotoxic eﬀects.
Each compound was tested with 11 diﬀerent concentrations
plus the control (absence of agent) using all the row-wells in
the 96-well plate and replicated 8 times, for each column of
the 96-well plate. The maximum dose-ranges of the 11 sub-
sequent serial dilutions of 4/3-fold dilutions for each com-
pound and the cell lines were described as follows:
- For NCI-H460: ME (200 µg mL−1), WE (200 µg mL−1), EL
(20 µM), VP-16 (200 µM) and CDDP (100 µM).
- For HeLa: ME (200 µg mL−1), WE (90 µg mL−1), EL
(10 µM), VP-16 (150 µM) and CDDP (50 µM).
- For MFC7: ME (200 µg mL−1), WE (150 µg mL−1), EL
(8 µM), VP-16 (160 µM) and CDDP (60 µM).
- For HepG2: ME (200 µg mL−1), WE (150 µg mL−1), EL
(10 µM), VP-16 (200 µM) and CDDP (30 µM).
2.4. Data normalization
In cellular growth media, the maximum response achieved by
the application of the anti-tumor agent at suﬃciently long
times would be the complete death of all cells, producing
asymptotic responses that would correspond to the total per-
centage of the tumor cell population mixed in the solution.
Consequently, the spectrophotometric inhibition responses (I)
should be carefully standardized. Therefore, before the data
are analyzed, the response (R) must be normalized as a func-
tion of the maximum inhibition value (Imax) that can be
achieved, as follows:
R ¼ ðI=ImaxÞ  100 ð1Þ
This simple normalization will transform the R as a func-
tion of the inhibited population cells in percentage. The Imax
corresponds to the spectrophotometric values produced by the
control response (absence of any agent) that should be
included in each analytical test using as many replicates as
possible and between diﬀerent tests of the same cellular line it
can be used as an indicator of the reproducibility of the results
generated. The I value corresponds to the spectrophotometric
inhibition responses achieved at diﬀerent doses of the agent
tested.
The normalization of raw data adjusts the resulting sample
variation (human error, excessive or defective dilution,
number of red blood cells present, etc.). Fitting the normalized
data would result in a significant increase in the reproducibil-
ity and accuracy of the results obtained, but not in a signifi-
cant change in the parameters produced.
2.5. Formal mathematical expressions from the dose–
response theory and related fields of study
All the models are formulated as a function of the dose (D)
and they are reparametrized to explicitly show the asymptotic
value K and the dose corresponding to the half-maximum
(K/2) inhibition response known as the LD50 value. These
models with three parameters would present an additional
shape parameter a.
2.5.1. First-order functions without intercept
M1: Michaelis–Menten equation. Michaelis and Menten27
published their now classic paper in which they showed that
the rate of an enzyme reaction is proportional to the concen-
tration of the enzyme/substrate complex predicted by the
Michaelis–Menten equation with rigor and precision.28 Since
then, the equation has been used successfully in many other
fields of study to describe symmetrical hyperbolic non-linear
responses. The expression can be written as follows:
RðDÞ ¼ K ½D=ðLD50 þ DÞ: ð2Þ
M2: Bertalanﬀy equation. A simplification of a more complex
four parameter equation,21 the Bertalanﬀy equation has been
applied to describe potential and first order responses. The
expression can be written as follows:
RðDÞ ¼ Kð1 2D=LD50Þ: ð3Þ
2.5.2. Sigmoid functions with intercept
M3: Verhulst growth equation. The so-called Verhulst model,
first proposed as a model of population growth29,30 or logistic
growth curve, is one of the simplest of the S-shaped growth
curves. Authors have used the Verhulst equation in diﬀerent
fields of study including the dose–response one31–34 and can
be written in the following functional form:
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RðDÞ ¼ K=f1þ exp½aðLD50  DÞg: ð4Þ
M4: Gompertz growth equation. The Gompertz equation,
Gompertz (1825),35 has been altered into growth curve analysis
(initial value R0 ≠ 0) for the description of tumors and micro-
organisms, among others.36 The equation, known as a
Gompertz curve, is now used in many areas to analyze those
time series where growth decreases at the start and termin-
ation periods. The equation can be described as follows:
RðDÞ ¼ Kf1 2exp½aðDLD50Þg: ð5Þ
2.5.3. Sigmoid functions without intercept
M5: Weibull equation. What was first developed by Fréchet
(1927)37 and first applied by Rosin & Rammler (1933)38 to
describe a particle size distribution is today the well-known
Weibull distribution, named in honor of the author who
described its capabilities in detail39 and then applied it to
analyze the mechanical failure of machines.40 The distribution
equation to describe dose–response profiles can be written as
follows:
RðDÞ ¼ Kf1 exp½ln 2ðD=LD50Þag: ð6Þ
M6: Hill equation. Hosselfed IV (1822)41 suggested a way to
describe the tree growth, an equation that was lately reinter-
preted to measure the rate of mortality. The equation was
popularized after the application by A.V. Hill42 to describe the
equilibrium relationship between oxygen tension and the sat-
uration of hemoglobin. In pharmacology, the Hill equation
has been extensively used to analyze quantitatively the drug–
receptor relationships43 by describing the non-linear dose–
response relationships:
RðDÞ ¼ K=½1þ ðLD50=DÞa: ð7Þ
M7: Modified Verhulst equation. The Verhulst equation29,30
can be transferred from its habitual formulation (as a model
for describing autocatalytic kinetics, or a biological growth) to
the context of the dose–response relationships eliminating the
intercept (to make R0 = 0),
44 whereby its form would be:
RðDÞ ¼ K=f1þ exp½aðLD50  DÞg  K=f1þ expðaLD50Þg: ð8Þ
M8: Modified Gompertz equation. Gompertz (1825)35
suggested that a “law of geometric progression pervades” in
mortality after a certain age and with the rate of mortality.
This equation was designed to describe the age distribution of
the human population. It has been successfully applied to
many biological processes demonstrating suﬃcient flexibility.
It has also been called the exponential decay function.45 The
equation can be presented as follows:
RðDÞ ¼ Kf1 2½ðexpðaDÞ1Þ=ðexpðaLD50Þ1Þg: ð9Þ
M9: Richards–Chapman equation. The trademark of the
Richards–Chapman equation is its flexibility. Although it was
first reported by Mitscherlich (1919),46 it became known after
the publication of Richards (1959).47 The Richard–Chapman
function is a modification of the Bertalanﬀy function. It is yet
another three-parameter model that behaves similarly to the
Weibull distribution, which has an upper asymptote and goes
through the origin. Researchers have used this model for
diﬀerent purposes and diﬀerent fields including the dose–
response one, finding a successful performance.48 The
equation can be written as follows:
RðDÞ ¼ K ½1 ð1 21=aÞD=LD50 a: ð10Þ
2.6. Fitting procedure to the mathematical models
All fitting procedures, coeﬃcient estimates and statistical cal-
culations were performed on a Microsoft Excel spreadsheet.
Fitting and statistical analysis of the experimental results to
the proposed equations are as follows:
2.6.1. Coeﬃcient determination. Parametric estimates
were performed by minimization of the sum of quadratic
diﬀerences between observed and model-predicted values,
using the nonlinear least-squares (quasi-Newton) method pro-
vided by the macro Solver in Microsoft Excel 2003,49 which
allows a quick testing of a hypothesis and its consequences.50
2.6.2. Coeﬃcient significance and model consistency.
The parametric confidence intervals were determined by
incorporating the ‘SolverAid’ macro (Prieto et al., 2012)12
for estimating the confidence intervals. The model was simpli-
fied by dropping those terms, which did not show a statisti-
cally significant p-value of >0.05. The Fisher F test (α = 0.05)
was used to determine whether the constructed models were
adequate to describe the observed data.51 Finally, the cor-
relation coeﬃcient R2 is interpreted as the proportion of the
variability of the dependent variable explained by the model.
2.7. Criteria used to assess the selection of the best model
2.7.1. Criteria based on model selection criteria (MSC). In
the present work, the AICc, BIC, RIC, Cp, R2adj, FPE and MSIC
criteria (Table A1†) were obtained directly by applying an Excel
spreadsheet using the Excel add-in ‘Solverstat’ macro.52 This
selected group is a combination of diﬀerent criteria that can
discriminate the models based on their goodness of fit, com-
plexity, overfitting and generalizability.
2.7.2. Additional intuitive criteria. Additional statistical cri-
teria to evaluate the mathematical models are based on the fol-
lowing common features:53 (a) the residual distribution; and
(b) the number of non-significant parameters (α = 0.05).
3. Results
3.1. Analysis of the most common dose–response
mathematical models for the description of cytotoxic
responses from TCLA by selective statistical criteria
Currently, the cytotoxicity reaction mechanism of tumor cells
in vitro is becoming increasingly better understood.3,4,54
However, the development of a mechanistic model to evaluate
the cytotoxic eﬀect of agents is very sophisticated and often
diﬃcult to accomplish due to the quantity of intermediate com-
ponents that need to be tested. In addition, the detailed
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mechanistic description of cytotoxic TCLA responses is even
more complex due to the heterogeneity of the cell lines used
that varies from one to the other assay, making it diﬃcult to
characterize in mechanistic terms the molecular pathways and
perhaps unfeasible to propose a single mechanistic system for
all the TCLA techniques.5,9 Therefore, researchers tend to
search for empirical general models, able to quantify and evalu-
ate the complex responses and summarize the results in simple
parameters.21,41,55,56 In this regard, previous reports from
related fields of study have reviewed diﬀerent empirical non-
linear mathematical expressions useful in biological systems
(such as microbiology, toxicology, pharmacology, immunology,
population dynamics, etc.) for wide diverse circumstances (ana-
lysis such as growth, kinetic, dose–response, etc.).20–22,24,48,57,58
These studies provide the key concepts to guide the develop-
ment of a standard solution for the TCLA.
Currently, it is unclear which model or models are consist-
ent or inconsistent with experimental data. A key problem is
that a direct comparison between the models has not been
carried out, in part because they have been formulated under
diﬀerent frameworks.59 To make sense from the diversity of
TCLA quantification criteria, a variety of verbal and mathemat-
ical ones are assessed. Next, the two parameter equations
(Bertalanﬀy and Michaelis–Menten equations) and the three-
parameter sigmoidal group of functions with intercept
(Verhulst and Gompertz equations) and without intercept
(Weibull, Hill, modified Gompertz, Richards–Chapman and
modified Verhulst equations) are tested with rigorous and
selective statistical criteria against experimental data specifi-
cally obtained to determine the most eﬃcient model solution.
3.1.1. Selection by statistical model selection criteria
(MSC). The usefulness of MSC to choose the best solution and
model is well-documented (Rivers & Vuong, 2002).74 A model
should be complex enough to extract the regularities in data,
but simple enough to not overfit it and thereby, reduce produc-
tiveness. MSC adjust the goodness of fit in order to penalize
model complexity, overfitting and lack of generalizability.
Currently, there are a variety of MSC available (Forster, 2000;
Myung & Pitt, 2004),75,76 but there is no one criterion that can
lead to a perfect choice (Roland T. Rust, Simester, Brodie, &
Nilikant, 1995).77 A summary of the MSC used to evaluate the
results obtained for the nine models is given in Table A1†
(AIC, AICc, BIC, RIC, Cp, R2adj, FPE, MSIC, and MA
2 criteria).
Experimental data used to test the models were the dose–
responses of 3 commercial agents (EL, VP-16 and CCDP, as a
single compound) and 2 natural extracts (ME and WE as a
mixture of compounds) in four tumor cell lines (NCI-H460,
HeLa, MCF-7 and HepG2) by one of the common TCLA tech-
niques, the SRB colorimetric assay (125 data points per agent
and tumor cell line).
Table 1 reports the estimated numerical values and confi-
dence intervals at a level of 95% for each of the parameters K,
LD50 and a of eqn (2)–(10), after fitting the dose–response
values of four tumor cell lines (NCI-H460, HeLa, MCF-7 and
HepG2) by the SRB colorimetric assay for screening the eﬀects
of 3 commercial agents (EL, VP-16 and CCDP, as a single com-
pound) and 2 natural extracts (ME and WE as a mixture of
compounds). These parametric values were used to test the
nine models selected from the bibliography (eqn (2)–(10)). The
statistical value of the correlation coeﬃcient R2 is presented as
proof of the fitting results obtained. The italicised parametric
values are non-significant and therefore, the fitting result
should be considered as non-valid analysis.
Table 2 shows the model rank (Rk) obtained for each MSC
and the global ranking based on the ranking sum of each MSC
(∑Rk) for the five agents used for one tumor cell line
(NCI-H460) as a representative example of the work performed
for all other tumor cell lines. Model selection criteria help to
diﬀerentiate the most “true solution”. In the ESI, Tables A2, A3
and A4† show the results for HeLa, MCF-7 and HepG2 tumor
cell lines, respectively. In general, all statistical MSC analyses
have diﬀerent features of the models as described in Table A1†
providing eﬃcient solutions from diﬀerent statistical angles.
Finally, Table A5† reports the global ranking (∑Rk) for all
the four tumor cell lines (NCI-H460, HeLa, MCF-7 and HepG2)
and for all the agents experimentally tested using the SRB
assay (EL, VP-16, CCDP, ME and WE). These ranking values
were used to order the nine models selected from the biblio-
graphy (eqn (2)–(10)) from the most to the least eﬃcient one
for each tumor cell line and finally for all of them. The global
ranking (∑Rk) denoting the eﬃciency of the fitting analysis
for each of the tumor cell lines assessed, is as follows in a
decreasing order:
- For NCI-H460: Weibull > Hill > Chapman > VerhulstM >
GompertzM > Bertalanﬀy > Verhulst > Michaelis > Gompertz.
- For HeLa: Hill > Weibull > Chapman > VerhulstM >
Bertalanﬀy > GompertzM > Michaelis > Verhulst > Gompertz.
- For MFC7: Weibull > VerhulstM > Chapman > Hill >
GompertzM > Bertalanﬀy > Verhulst > Michaelis > Gompertz.
- For HepG2: VerhulstM > Weibull > Chapman > Hill >
GompertzM > Bertalanﬀy > Michaelis > Verhulst > Gompertz.
Therefore, in global terms the models most likely to be
correct, presenting a final global ranking, are as follows in a
decreasing order: Weibull > Hill > VerhulstM > Chapman >
GompertzM > Bertalanﬀy > Verhulst > Michaelis > Gompertz.
3.1.2. Additional intuitive criteria. The residuals should be
randomly scattered around zero to avoid autocorrelation.49
These residuals should not be grouped and should not
increase or decrease as a function of the independent variable.
In addition, a large group of runs in certain zones of the
residual plot indicate a cluster distribution suggesting a lack
of estimation or overestimations. In general terms, all the
models used showed a relatively good distribution of the
residuals. Only the Bertalanﬀy and Michaelis models showed
autocorrelations when the responses presented a sigmoid or
potential profile. All other models showed a relatively good dis-
tribution of the residuals and autocorrelation was not observed
(data not shown).
Another important aspect is the confidence in intervals at a
level of 95% for each parameter (reported in Table 1). The
parametric estimates in many cases led to large confidence
intervals and therefore, these parameters were considered not
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significant (italicised in Table 1). For example, the VerhulstM
and GompertzM showed many cases in which one or two para-
meters were found to be non-significant. Only the models of
Weibull, Hill and Chapman showed in all cases that all the
parameters were statistically significant (α = 0.05).
3.1.3. Advantages/disadvantages of each model solution
and final model selection. The non-linear model of the
Michaelis–Menten and Bertalanﬀy equations, which is a two
parameter solution, that only describes a very particular sym-
metrical hyperbolic case can adjust only first-order kinetic pro-
files, but fails to accomplish complex model solutions with
diﬀerent order levels such as potential and sigmoidal ones,
which in contrast are very common responses in the TCLA.
The other tested alternatives, the sigmoid group without
intercept (Weibull, Hill, Chapman, VerhulstM and GompertzM)
and the sigmoid group with intercept (Verhulst and Gompertz),
are models that cover the maximum possible responses in a 2D
frame (from potential to sigmoid profiles including the first-
order ones). However, they show some relevant diﬀerences that
may end-up being key characteristics that may make the diﬀer-
ence when analyzing TCLA. In order to properly understand and
to illustrate the diﬀerent capabilities of applying one or another
sigmoid group of functions, Fig. 1 shows the application of
these seven models in four specific cases typical in dose–
response analysis: case 1, a potential profile; case 2, a first-order
profile; case 3, a slightly sigmoid profile; and case 4, a strong
sigmoid profile. The models are simulated under the same para-
metric conditions for each case in order to be able to compare
the diﬀerences in the pattern profiles: the asymptotic K value is
established for all cases at a value of 100% of inhibition; the
LD50 is equal for all the models and placed in specific locations
for each case in order to magnify as much as possible the profile
diﬀerences (for cases 1 & 2 and cases 3 & 4, the LD50 is located
at the hypothetical value of 10% and 50% of the total dose units
measured, respectively); and the shape parameter a is adjusted
by means of least squares to minimize the diﬀerences between
each model. Since we are fitting each specific profile case to an
identical parametric value of K and LD50 the main diﬀerences
are only present in the initial and final stages. These diﬀerences
are in many cases diﬃcult to visualize and therefore, to illustrate
them in each case, an augment section at the early and final
stages is included. Additionally, each line is identified in a
decreasing order in each of the stages augmented.
As it was already underlined by other authors,13 proved by
the MSC results and visually illustrated in Fig. 1, the equations
with intercept (Verhulst and Gompertz) cause some problems,
and in general, it is preferable to consider the null response as
zero. The major issues arise when these models (with inter-
cept) describe the initial and final parts of the reaction. If used
in a real analysis of TCLA dose–responses, the fitting pro-
cedure would cause that the residual distribution and the cor-
relations between the observed and predicted data will show
deviations as a function of the dependent variable, which
would result in increasing the interval of confidence of the
parameters, reducing the correlation coeﬃcients (such as the
R2) and causing diﬃculty in the production of robust results.
Such deviations disappear when the fitting is performed with
model approaches without intercept. In general, the sigmoid
function without intercept is the best solution to fit individu-
ally the profiles corresponding to a series of increasing levels
of an agent. However, the models without intercept of
VerhulstM and GompertzM show other issues related to high
parametric confidence intervals (many of them are non-signifi-
cant) and poor ranking values by the MSC (see Table A5†), in
comparison with the other ones (Weibull, Hill and Chapman).
Therefore, Weibull, Hill and Chapman sigmoid models
without interception are found to be the most eﬃcient ones
with global ranking results better than the other alternatives.
Although the diﬀerences are narrow, the Weibull model shows
overall better results and therefore, without any doubt, can be
considered as the most appropriate solution for TCLA.
3.2. Extensive description of the capabilities of the
mathematical model selected for the dose–response
quantification of the inhibited population growth of tumor
cell lines
The Weibull model was described in detail by Weibull &
Sweden (1951).40 The model was adapted to analyze the mech-
anical failure of machines after an event was repeatedly
induced. If we consider the distribution of the number of
times that this event needs to be repeated to cause the
machine failure as doses to damage cells which may lead to
death, we have an analogy with mortality or inhibition of cells.
Therefore, it seems not a casual coincidence that this model
was the most appropriate solution.
The model transcribes the following power reaction aﬃnity
of agents to cells as a function of the dose (D):
AðDÞ ¼ bD ðc1Þ ð11Þ
in which A is the aﬃnity of agents to cells and b and c are para-
metric values. If the aﬃnity of agents of a population R
changes as a function of D (dR/dD) can be initially defined by
the following expression:
dR=dD ¼ AR: ð12Þ
Therefore, by inserting eqn (11) into (12) and integrating
the resulting expression, the basis of the Weibull model can be
obtained. By multiplying the resulting function by an asympto-
tic K parameter and rearranged60 to explicitly show the LD50
parameter, the following increasing inhibition or mortality can
be found as described initially in eqn (6):
RðDÞ ¼ Kf1 exp½ln 2ðD=LD50Þag: ð6Þ
In addition, the Weibull model is a versatile and flexible
equation with an intuitive shape parameter to define the poss-
ible type of profile that can adjust: (1) when a < 1 describes fac-
tionary-order kinetics; (2) when a = 1 describes a first-order
kinetics; and (3) when a > 1 produces a variety of sigmoidal
profiles that are the common solution for the system.
Although the use of all of them is not frequent, from this
equation, other essential parametric values for characterizing
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the inhibition process of tumor cells from TCLA can be com-
puted. The analysis results can be directly obtained from the
parameters of eqn (6) or with some algebraic modifications of
eqn (6) reparametrized to make such values explicit in an inde-
pendent equation and therefore, their confidence intervals can
be computed. Next the most useful values for cytotoxic analysis
of the response inhibition in TCLA are:
(1) The dose that shows the maximum aﬃnity of the reac-
tion process (DA) that translates the % inhibition achieved by
increase of each dose unit, which can be computed directly or
explicitly as follows:
DA ¼ K ln 22LD50 ; therefore RðDÞ ¼ K exp ðln 2Þ
1a 2DA
K
 D
 a 
ð13Þ
(2) The lag-phase parameter (LDλ, dose units), that accounts
for the dose value in which the rate of the process can be con-
Fig. 1 Diﬀerences between the seven-sigmoid group of models to ﬁt speciﬁc cases of the TCLA dose–responses. Four diﬀerent cases are pre-
sented: case 1, a potential proﬁle; case 2, a ﬁrst-order proﬁle; case 3, a slightly sigmoid proﬁle; and case 4, a strong sigmoid proﬁle.
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sidered negligible and corresponds to the intersection point
obtained at the dependent variable axis (dose units) by a linear
extrapolation tangent to the curve at the inflection point:
LDλ ¼ LD50ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ln 2a
p G1=a þ e
G  1
aGGeG
 
; where G ¼ a 1
a
therefore RðDÞ ¼ K exp  G1=a þ e
G  1
aGGeG
 
D
LDλ
 a  ð14Þ
(3) Any dose corresponding to any response R representing
any lower fraction of K (or LDn) can be computed using the fol-
lowing expression:
LDn ¼ LD50fln½1 ðRn=KÞ= ln 2g1=a ð15Þ
by providing the n values of eqn (15) between 0 and 100% any
desired dose level of the response would be achieved (LD10,
LD25, LD75, LD95, etc.). As in the previous parametric values,
they can be reparametrized into an explicit equation to
compute the confidence intervals. In general, for the compu-
tation of LDn corresponding to a response equivalent to n% of
the maximum one (nK/100), the reparametrized equation is:
RðDÞ ¼ Kf1 exp½lnð1 0:01nÞðD=LDnÞag ð16Þ
(4) An additional quantitative feature is the dose that
elapses 100% of the tumor cell inhibition or in other words,
the dose at which the response reaches the asymptotic para-
metric value of K (LDK). This value can be obtained by arran-
ging eqn (16) with a tricky simplification (considering 100% of
the response as ∼99.995%) as follows:
RðDÞ ¼ Kf1 exp½10ðD=LDK Þag ð17Þ
Therefore, the general characterization of the inhibition
process of tumor cells from TCLA can be described rigorously
with the combinatory information provided by the parameter
criteria of LD50, DA, LDλ, LDK or any desired LDn values.
Although the explicit eqn (13), (14), (16) and (17) have the
same total number of parameters as eqn (6), the algebraic
manipulation is less operative and less practical than the stan-
dard eqn (6) with the LD50 parameter.
61
3.3. Problems with each of the possible parameters from the
mathematical analysis that could be used as a single criterion
to analyze the dose–response results of TCLA
When describing the cytotoxicity of a new agent, most of the
research studies focus only on the production of the LD50, but
this parametric value on its own is much less reliable than
generally anticipated. In fact, on their own any of the criteria
values pointed out previously (LD50, DA, LDλ, LDK or any
desired LDn values) cannot produce reliable results in com-
parative terms with other agents even if the results are very
reproducible.
To illustrate this fact, Fig. 2 shows a representation of the
problems associated with the application of the possible para-
metric values to describe the dose–response inhibition of
tumor cells. In the first part of Fig. 2 (part A), a graphical
identification of the possible characterizing parameters for the
analysis of TCLA is presented (including LD50, DA, LDλ and
LDK). In the second part of Fig. 2 (part B) the lack of reliability
of all the parametric criteria values is illustrated by means of
simulation with eqn (6), (13), (14) and (17). By simulating and
comparing the inhibition activity of five hypothetical agents
(X1 to X5) for each of the characterizing parameters four
diﬀerent case scenarios (cases B1 to B4) illustrate the associ-
ated problems and are depicted in detail as follows:
- For LD50 parametric criteria (case B1): the graphical illus-
tration shows how five well diﬀerentiated profile responses of
agents (X1 to X5) would present identical LD50 values, but
diﬀerent DA, LDλ and LDK parametric values.
- For DA parametric criteria (case B2): the illustration pre-
sents five well diﬀerentiated profile responses (X1 to X5) that
would lead to identical DA values, but diﬀerent LD50, LDλ and
LDK parametric values.
- For LDλ parametric criteria (case B3): the illustration pre-
sents five diﬀerentiated profile responses (X1 to X5) that would
lead to identical LDλ values, but diﬀerent LD50, DA and LDK
parametric values.
- For LDK or any desired LDn parametric criteria (case B4):
the illustration presents five diﬀerentiated profile responses
(X1 to X5) that would end up with identical LDK values, but
diﬀerent LD50, DA and LDλ parametric values. This trend can
be applied to any desired LDn values that produces a specific
percentage of the mortality response.
These problems have been studied in other fields, notably
in theoretical biology, in which the estimations are proposed
to be based on the combinatory analysis of many parametric
values for comparative purposes. Probably, because an unreli-
able solution has been found, as those illustrated in Fig. 2
(part B), when considering the response of only one para-
metric value. To add more complexity to the analytical charac-
terization of the responses, diﬀerent hypotheses could provide
more complex scenarios with similar estimates. The impreci-
sion of the estimates is generally larger than the diﬀerences
between the approaches used. Moreover, all parametric results
are highly dependent on the quality of the dataset. Thus, it
becomes clear that when, any of these criteria used on their
own as the single general response value of the action of an
agent, they are very dependent on the shape of the curve and
could produce easily untrustworthy comparative conclusions.
Therefore, all parametric analyses need to be presented in con-
junction to be able to compare the inhibitory activity of agents
rigorously, and the more criteria are used the less would be
the chances of being tricked by the eﬀects accounted for.
3.4. Model application to experimental results specially
designed to validate the model
Once that it has been performed, a detailed analysis (in stat-
istical terms) of the most eﬀective model solution for TCLA
dose–responses, an extensive description of the parametric
values that can be derived from that model solution and a dis-
cussion of the advantages and disadvantages of using one or
another parametric value to characterize the TCLA dose–
responses, in this section the selected model solution of eqn (6)
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would be finally applied to describe, characterize, quantify and
predict rigorously the dose response eﬀects of agents from a
range of TCLA.
Fig. 3 shows the fittings of the dose–response model of eqn
(6) to the data obtained by the SRB colorimetric assay in four
tumor cell lines (NCI-H460, HeLa, MCF-7 and HepG2) for
screening the eﬀects of the three commercial agents (EL,
VP-16 and CCDP) and two natural extracts (ME and WE as a
mixture of compounds). The experimental dose–responses of
125 data points per agent and tumor cell line are represented
by the circles (○), meanwhile the lines (—) represent the fit-
tings achieved by the mathematical model selected. Table 3
shows the parametric estimations of eqn (6) and the additional
model values (eqn (13), (14) and (17) in order to obtain LD50,
DA, LDλ and LDK parametric values, respectively), confidence
intervals (α = 0.05) and statistical information of the dose–
response results of the inhibition.
The fitting of results was always robust and consistent
(p-values < 0.001 from Fisher’s F test), the residuals were ran-
domly distributed and autocorrelations were not observed by
the Durbin–Watson test (data not shown). The statistical ana-
lysis, parameter assessment tools and model prediction uncer-
tainties are in agreement accordingly. Furthermore, the corre-
lation coeﬃcients R2 between the predicted and observed
values were always greater than 0.93, with a wide majority of
the fittings superior at 0.97.
3.5. Some examples of the analytical capabilities of the
parametric values produced
Focusing on the standard commercial compounds and
knowing that in each well 1.0 × 104 cells were placed (in 200 µL
of final volume), we can extend the analysis in terms of mole-
cules needed to inhibit the whole cell population. For
example, for the cell line NCI-H460, for the EL case and using
the parametric value of LDK (31.6 ± 6.1 µM of EL, Table 3),
3.80 × 1011 molecules of EL were needed to inhibit each tumor
cell in global terms (average inhibitory rate of molecules
needed to inhibit the entire cell population). Because the
process was non-linear, meaning that this global value varies
depending on the dose, this average value cannot be computed
by the LD50 as it depends on the profile of the curve.
Another interesting fact of the non-linear process here
described is the maximum killing rate achieved by the com-
pound, which it can be computed by using the parametric
value of DA (33.96 ± 1.1% Inh per µM for EL for NCI-H460 as
an example, Table 3), which in this case was 3.55 × 1010 mole-
Fig. 2 Part A: Identiﬁcation of the possible parameters for the analysis of TCLA responses by a conventional graphical representation. In the top
part, the percentage of inhibition of tumor cells is plotted against the dose–response of a simulated agent. In the bottom part, the rate of the inhi-
bition is presented (the corresponding numerical derivative). Part B: Illustration of the problems associated with the application of the possible para-
metric values to describe the dose–response inhibition of tumor cells: case B1, all proﬁles present the same LD50 values; case B2, all proﬁles present
the same DA values; case B3, all proﬁles present the same LDλ values; and case B4, all proﬁles present the same LDK values.
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cules of EL that were needed to inhibit each tumor cell. At the
maximum rate value of the process, the cells were inactivated
with ∼11 times less molecules than at the average value com-
puted above with the parametric value of LDK.
For all other compounds in each cell line the following
values (molecules per cell) were identified:
- For NCI-H460: EL (as described, 3.80 × 1011 with the
maximum rate value of 3.55 × 1010 using ∼11 times less mole-
cules), VP-16 (1.55 × 1012; 4.42 × 1011; ∼4) and CDDP (1.55 ×
1012; 2.06 × 1011; ∼5).
- For HeLa: EL (1.87 × 1011; 3.72 × 1010; ∼5), VP-16 (7.06 ×
1012; 6.90 × 1011; ∼10) and CDDP (7.47 × 1011; 1.76 × 1011; ∼4).
Fig. 3 Experimental dose–response data (○) to four tumor cell lines (NCI-H460, HeLa, MCF-7 and HepG2) by the SRB colorimetric assay for
screening the eﬀects of three commercial agents (EL, VP-16 and CCDP, as a single compound) and two natural extracts (ME and WE as a mixture of
compounds). These data (125 data points per agent and tumor cell line) were used to test the nine models selected from the bibliography. Lines (—)
represent the ﬁttings achieved by the mathematical model selected. The obtained parametric ﬁtting values are presented in Table 3.
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- For MFC-7: EL (1.47 × 1011; 3.77 × 1010; ∼4), VP-16 (2.28 ×
1012; 6.02 × 1011; ∼4) and CDDP (7.21 × 1011; 2.57 × 1011; ∼3).
- For HepG2: EL (3.93 × 1011; 4.83 × 1010; ∼8), VP-16 (7.02 ×
1012; 1.55 × 1012; ∼5) and CDDP (2.10 × 1012; 9.01 × 1010; ∼23).
Therefore, the application of these parametric values of the
dose–response curve oﬀers new formats of comprehending the
dose eﬀects of the compounds assessed, which can open to a
greater extent the analytical capabilities of researchers and
therefore, its conclusions. These new analytical capabilities
can be used in complex scenarios. As an example, when
combining compounds in pharmacology for synergistic
purposes, it is likely that by applying the doses of these
compounds at their respective maximum rates of inhibition
(or maximum eﬀective doses), the synergistic eﬀects, if any,
will show their maximum synergistic interaction. The maximum
eﬀective doses at which the DA occurs are easily computable
by eqn (13).
This analysis can be transferred to the mixture of com-
pounds of the extracts (in this case ME and WE). Because the
mixture is so complex, it will be nearly impossible to establish
relationships between molecules and their eﬀects on the cells,
but its essence is preserved.
3.6. Potential equivalent cytotoxic activity of methanol and
water extracts
Beyond quantitative diﬀerences, WE and ME extracts promote
the cytotoxic activity in the four tumor cell lines. Note that
the dose units (D) for ME and WE are in µg mL−1, meanwhile
for EL, VP-16 and CCDP the units are in a standard form of
µM (µmol L−1). Although the results between pure com-
pounds and a mixture of compounds are not comparable, the
total computable eﬀects of the mixture of compounds (syner-
gistic and antagonistic) present in the extracts can be com-
pared in a concentration format to the commercial standards.
In order to compare the mixture of compounds with standard
molecules, the results of Table 3 of EL, VP-16 and CCDP need
to be expressed in µg mL−1. Such a conversion is presented in
Table A6† and a visual comparison of the transformed model
parametric values (LD50, DA, LDλ and LDK) is presented in
Fig. 4. As the parameter LDλ was not meaningful for all
responses it will not be used for discussion. Using the equiv-
alences of the relevant parametric values (LD50, DA, and LDK)
between each extract mixture of compounds (ME and WE)
against each pure commercial compound (EL, VP-16 and
CCDP) for each tumor cell line some extra relevant infor-
mation will illustrate the problems highlighted in this docu-
ment regarding the problem of using only one value as stan-
dard criterion. As an example, for the ME in the NCI-H460
cell line the equivalent values of EL show for the LD50 ∼308
less equivalent eﬀective values, for the DA ∼109 and for
LDK ∼25.
For the ME all the equivalent values for the commercial
compounds were the following:
- For NCI-H460: EL (as described, LD50 ∼308; DA ∼109; LDK
∼25), VP-16 (LD50 ∼5; DA ∼4; LDK ∼3) and CDDP (LD50 ∼30; DA
∼15; LDK ∼8).
Table 3 Parametric estimations, conﬁdence intervals (α = 0.05) and statistical information of the dose–response results of the inhibition process of
four tumor cell lines (NCI-H460, HeLa, MCF-7 and HepG2) by the SRB colorimetric assay for screening the eﬀects of three commercial agents (EL,
VP-16 and CCDP, as a single compound) and two natural extracts (ME and WE as a mixture of compounds). The samples were ﬁtted to the model
selected of eqn (6) and the additional model rearrangements (eqn (13), (14), (16) and (17)) in order to obtain LD50, DA, LDλ and LDK parametric values.
The dose units (D) ME and WE are in µg mL−1, meanwhile the units for EL, VP-16 and CCDP are in µM. Table A6 shows the results in a comparative
mode in µg mL−1 for all compounds
Cellular line &
compound
Main fitting parameters Other valuable parameters
Statistics
K (% Inh) LD50 (D) a (—) DA (% Inh per D) LDK (D) LDλ (D) R
2
NCI-H460 ME 100.0 ± 9.3 58.8 ± 6.4 1.98 ± 0.29 1.27 ± 0.2 196.9 ± 12.4 11.91 ± 3.00 0.9785
WE 100.0 ± 8.1 47.0 ± 5.2 1.73 ± 0.11 1.12 ± 0.2 187.2 ± 13.5 6.50 ± 1.88 0.9347
EL 100.0 ± 12.3 0.8 ± 0.3 0.65 ± 0.06 33.96 ± 1.1 31.6 ± 6.1 0 0.9546
VP-16 100.0 ± 6.4 18.8 ± 2.6 1.25 ± 0.16 2.73 ± 0.5 128.5 ± 12.9 0.43 ± 0.17 0.9667
CCDP 100.0 ± 7.1 6.5 ± 1.3 0.93 ± 0.17 5.85 ± 1.6 84.7 ± 11.4 0 0.9817
HeLa ME 100.0 ± 21.5 50.2 ± 14.8 1.27 ± 0.10 1.04 ± 0.2 329.6 ± 32.4 1.38 ± 0.54 0.9359
WE 100.0 ± 4.5 21.2 ± 1.4 1.32 ± 0.19 2.85 ± 0.5 129.6 ± 12.3 0.79 ± 0.30 0.9696
EL 100.0 ± 26.7 1.2 ± 0.5 0.94 ± 0.16 32.42 ± 3.7 15.5 ± 2.1 0 0.9474
VP-16 100.0 ± 26.8 15.4 ± 7.4 0.66 ± 0.06 1.75 ± 0.7 586.4 ± 11.3 0 0.9751
CCDP 100.0 ± 12.4 6.8 ± 1.2 1.08 ± 0.04 6.85 ± 1.6 62.0 ± 7.2 0.02 ± 0.01 0.9690
MFC7 ME 100.0 ± 12.2 57.9 ± 8.8 1.53 ± 0.34 1.04 ± 0.2 275.5 ± 22.4 5.06 ± 1.65 0.9772
WE 100.0 ± 12.9 44.3 ± 7.1 1.35 ± 0.15 1.38 ± 0.3 262.2 ± 24.3 1.89 ± 0.70 0.9683
EL 100.0 ± 21.0 1.4 ± 0.4 1.12 ± 0.42 31.92 ± 7.2 12.2 ± 1.4 0.01 ± 0.00 0.9685
VP-16 100.0 ± 10.2 25.0 ± 3.6 1.18 ± 0.29 2.00 ± 0.4 189.0 ± 20.0 0.33 ± 0.14 0.9847
CCDP 100.0 ± 14.7 12.2 ± 2.2 1.50 ± 0.31 4.69 ± 0.8 59.9 ± 5.0 0.97 ± 0.32 0.9810
HeG2 ME 100.0 ± 60.4 96.0 ± 7.6 1.28 ± 0.44 0.45 ± 0.1 620.2 ± 60.4 2.86 ± 1.11 0.9639
WE 100.0 ± 17.6 38.2 ± 9.0 1.25 ± 0.22 1.21 ± 0.2 258.6 ± 25.8 0.92 ± 0.37 0.9772
EL 100.0 ± 82.2 1.2 ± 1.9 0.72 ± 0.01 24.93 ± 2.7 32.6 ± 5.7 0 0.8775
VP-16 100.0 ± 38.7 43.4 ± 2.5 0.92 ± 0.07 0.78 ± 0.2 583.0 ± 79.1 0 0.9831
CCDP 100.0 ± 17.3 1.5 ± 0.9 0.50 ± 0.01 13.39 ± 6.7 174.7 ± 43.7 0 0.9851
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- For HeLa: EL (LD50 ∼169; DA ∼127; LDK ∼86), VP-16 (LD50
∼6; DA ∼3; LDK ∼1) and CDDP (LD50 ∼25; DA ∼22; LDK ∼18).
- For MFC-7: EL (LD50 ∼165; DA ∼125; LDK ∼92), VP-16
(LD50 ∼4; DA ∼3; LDK ∼2) and CDDP (LD50 ∼16; DA ∼15; LDK
∼15).
- For HepG2: EL (LD50 ∼335; DA ∼224; LDK ∼77), VP-16
(LD50 ∼4; DA ∼3; LDK ∼2) and CDDP (LD50 ∼220; DA ∼99; LDK
∼12).
For the WE all the equivalent values for the commercial
compounds were the following:
- For NCI-H460: EL (LD50 ∼246; DA ∼123; LDK ∼24), VP-16
(LD50 ∼4; DA ∼4; LDK ∼2) and CDDP (LD50 ∼24; DA ∼17; LDK ∼7).
- For HeLa: EL (LD50 ∼71; DA ∼46; LDK ∼34), VP-16 (LD50
∼2; DA ∼1; LDK ∼0.4) and CDDP (LD50 ∼10; DA ∼8; LDK ∼7).
- For MFC-7: EL (LD50 ∼127; DA ∼94; LDK ∼87), VP-16 (LD50
∼3; DA ∼2; LDK ∼2) and CDDP (LD50 ∼12; DA ∼11; LDK ∼15).
- For HepG2: EL (LD50 ∼133; DA ∼83; LDK ∼32), VP-16 (LD50
∼1; DA ∼1; LDK ∼0.75) and CDDP (LD50 ∼88; DA ∼37; LDK ∼5).
Therefore, as it can be illustrated using values LD50 will
underestimate the equivalent results of WE and ME in an
average term about ∼2 times than if we use DA and up to ∼5
times if we use LDK. Presenting some extreme cases, as an
example for the CDDP in the HeG2 cell line in which by using
the LD50 or LDK will show equivalent diﬀerences underestimat-
ing the activity of WE ∼18 times. In another illustrative case,
for the VP-16 in HeLa cell line the LD50 shows that the WE
needs ∼2 times the dose values to achieve the same response,
but when the analysis is performed based on the LDK para-
metric value the eﬀect is inverted showing ∼2 times higher
cytotoxic eﬀects of the WE than the VP-16.
In consequence, these results corroborate the conclusions
previously discussed, that all parametric analyses need to be
presented in conjunction to be able to compare the inhibitory
activity of agents rigorously, and the more criteria are used the
less would be the chances of being tricked by the eﬀects
accounted for.
4. Conclusions
Despite the existence of very rigorous results, the advances in
the manipulation of cell lines, the technological sophistication
of equipment to determine at a molecular level the cellular
changes and the mechanization of the TCLA response, the
quantification of the dose-eﬀect results has been left aside as
they were described between two and three decades ago, when
the access to computerized systems was limited. Except for
lineally dependent responses, in almost all the other cases,
which are the most frequent ones in biology, non-linear
expressions must be used to properly describe the eﬀects of
variables such as the dose ones. Avoiding the explicit appli-
cation of mathematical models for the analysis of TCLA in
endpoint assay responses could end in lower results reproduci-
bility, which often would lead to an excessive quantity of
restrictions in the protocol application. Similar to other
authors in the cancer research area,62–69 we suggest alternative
forms to the simplistic ways of characterization of cytotoxic
responses of TCLA and attempt to address this issue by
bringing across theoretical, mathematical concepts from
related areas to overcome the existing quantification diﬃcul-
ties and propose a unified criterion.
The range of mechanistic or empirical non-linear
expressions available is large70 and the preferable options are
always those models that have a lower number of parameters
and models with parameters that provide direct meaning of
the processes under analysis.53,58 In this sense, for the dose–
response description of the mortality (inhibition) or survival
(viability) rates of a tumor cell, they can be assessed by a group
Fig. 4 Graphical comparison of the main parametric values to assess
the experimental responses. Parametric values were obtained by eqn (6)
for LD50, eqn (13) for DA, eqn (14) for LDλ and eqn (17) for LDK. Error bars
display the conﬁdence intervals (α = 0.05) of the parametric values.
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of alternatives that already have been well described in the
bibliography covering a wide spectrum of profile responses,
from potential to sigmoid ones, with and without inter-
cepts.22,48,57,71 Independent of the intrinsic mechanistic rate
of processes that those models translate, the empirical descrip-
tion of the cytotoxic eﬀect of those processes show a wide
range of 2D responses (hyperbolic, potential, first-order and
sigmoidal). In general, most of the above models tested can be
transferred to study the cytotoxic eﬀects in TCLA and help to
compute, in a proper form, the inhibitory features produced
by diﬀerent agents. Those models would be able to produce
key parameters to summarize the responses and they can be
used to quantify the eﬀect of diﬀerent chemicals. Since there
are many model alternatives able to fit reasonably well the
cytotoxicity in TCLA, a selection process is needed to deter-
mine the model that most eﬃciently describes and predicts
the dose–response eﬀects of agents.59 The results of the com-
parison of several mathematical models for describing the
experimental profiles highlighted the fitting and description
capacities. The Weibull model was selected and tested using
experimental results obtained for validation purposes and
results from other authors under diﬀerent conditions.
Accurate and statistically consistent fittings were obtained in
all the cases.
From the Weibull model, a set of parameters was proposed
as criteria to aid the comparison of the cytotoxic results
between agents (LD50, DA, LDλ, LDK or any desired LDn values).
All these parametric values are based on the first principles or
with clear geometric and physical meaning, which describe
the cytotoxic characteristics completely. However, as demon-
strated, on their own none of them can produce reliable
results and all parametric analyses need to be presented in
conjunction to be able to compare the inhibitory activity of
agents.
In consequence, the results prove that: (1) the preference
for apparently simple quantification procedures, routinely
applicable with minimal calculation requirements, is not very
justifiable in our days, given the availability of computational
applications and microplate readers, whose combination pro-
vides adequate tools to work with data sets that allow to
perform accurate evaluations with non-linear mathematical
models; (2) after a detailed statistical analysis of the dose–
response models typically applied to a selected data set, the
most eﬃcient mathematical model for the description of the
cytotoxic responses of TCLA methods is selected; (3) the
reduction to study the dose–response only at LD50 values could
lead frequently to unreliable results; and (4) other additional
parametric values such as the maximum and average rate
process, lag-phase period values, among others, should be pre-
sented along with the LD50 values in order to properly describe
the cytotoxic eﬀects of agents. Such results can be easily
extrapolated to the other in vitro and in vivo assays generally
used to determine the mortality patterns of tumor cells.
However, as stated by many authors before, living systems
are exposed to agents and any particular eﬀect may be
expected to be a function of both the dose in the external sur-
roundings and the exposure time, in a bivariate form.58,72 This
present work deals with the responses of in vitro TCLA assays
performed in the end-point format, pinpointing the contro-
versy around the analyses of the dose–response eﬀects. We are
aware that the traditional end-point studies suﬀer from an
essential defect by supposing that at any time measured, the
same dose–response parametric values would be pro-
duced.5,9,10,15,16 However, this only occurs in an ideal case
scenario, when all time-course dose–responses show the first-
order profiles, and in all other scenarios the dose–response
parametric values will change at diﬀerent time analysis.14
Therefore, this study is the first approach to establish, in a
standard format, the basis for future work including the time-
course eﬀects in a multivariable model allowing to compute
jointly time-dose dependent responses.13,14,73
Abbreviations
General notations
TCLA Tumor cell line assays
ATP Adenosine triphosphate
DMSO Dimethyl sulfoxide
TCA Trichloroacetic acid
HBSS Hanks’ balanced salt solution
Tris Tris(hydroxymethyl)aminomethane,
(HOCH2)3CNH2
TrypLE
express
Replacement of trypsin from animal origin
FBS Fetal bovine serum
R2 Linear correlation coeﬃcient
R Response of the % of inhibition
Tumor cell lines
NCI-H460 Human cell line of non-small cell lung carcinoma
HeLa Human cell line of cervical carcinoma
MCF-7 Human cell line of breast adenocarcinoma
HepG2 Human cell line of hepatocellular carcinoma
Most frequent techniques for the evaluation of cell
proliferation in cytotoxicity assays
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium
XTT 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide
SRB Sulforhodamine B
Inhibitor agents of tumor cell growth
ME Methanolic extract of Achillea millefolium L. plant
WE Water extract of Achillea millefolium L. plant
EL Ellipticine
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VP-16 Etoposide
CDDP Cisplatin
Parametric values to describe the dose–response eﬀect of
agents
K Asymptote value of the response (% of death cells)
LD50 Dose units at which the 50% of R is achieved
a Sigmoid shape parameter (dimensionless)
LDλ Dose units at which the minimum R is detected
DA Dose with the maximum aﬃnity in the response reac-
tion (R per dose unit)
LDK Dose units at which the maximum R is detected
Model selection criterion
AIC Akaike information criterion
AICc Akaike information criterion corrected
BIC The Schwartz or Bayesian information criterion
RIC Residual information criterion
Cp Mallows criteria
R2adj Adjusted correlation coeﬃcient of multiplied
determination
FPE Akaike’s final prediction error
MSIC Model selection criterion
MA2 Square model analysis
Mathematical models used
Michaelis–Menten Eqn (2)
Bertalanﬀy Eqn (3)
Verhulst Eqn (4)
Gompertz Eqn (5)
Weibull Eqn (6)
Hill Eqn (7)
Verhulst modified Eqn (8)
Gompertz modified Eqn (9)
Richards–Chapman Eqn (10)
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